This report provides an in-depth analysis of the US Extracorporeal Membrane Oxygenation (ECMO) Machine market, including market share, industry trends, drivers, opportunities, and growth forecasts from 2020 to 2035. The US market size was valued at USD 380 Million in 2025 and is anticipated to reach USD 1,020 Million by 2035, expanding at a CAGR of 9.2% from 2024 to 2035.
The economic impact of tariffs on "US Extracorporeal Membrane Oxygenation Machine".
US Extracorporeal Membrane Oxygenation Machine Market Growth Drivers
Increasing Prevalence of Cardiopulmonary Diseases: The rising incidence of respiratory and cardiac disorders, particularly among the aging US population, is significantly boosting the demand for advanced life-support devices, such as ECMO machines. According to Medtronic, growing numbers of heart failure and ARDS (Acute Respiratory Distress Syndrome) cases are prompting hospitals to invest in ECMO machines for critical care support. Improved survival rates associated with ECMO therapy in severe COVID-19 and non-COVID ARDS further drive market expansion.
Technological Advancements and Integration with Digital Health: Leading market players like Getinge have introduced next-generation ECMO systems with enhanced safety, real-time monitoring, and user-friendly interfaces. The integration of digital health platforms enables remote monitoring and predictive analytics for patient management, improving efficacy and expanding adoption across US hospitals. These technological innovations are encouraging newcomers and established providers to strengthen their product portfolios in the US market.
US Extracorporeal Membrane Oxygenation Machine Market Trends
Shift to Portable and Home-Based ECMO Devices: As seen with Abbott and other major companies, there is a distinct trend toward more compact, portable ECMO machines. These devices are designed for inter-hospital patient transfer or potential home use for stable patients, broadening the potential patient base and facilitating early hospital discharges.
Emergence of Artificial Intelligence for ECMO Management: Companies such as Siemens Healthineers are actively developing AI-driven monitoring protocols that aid in optimizing ECMO treatment strategies. AI-enhanced solutions offer real-time data analytics, risk prediction, and decision-making support, allowing clinicians to personalize therapies and lower complications in ECMO-supported patients.
US Extracorporeal Membrane Oxygenation Machine Market Opportunity
Rising Investments in Pediatric and Neonatal ECMO: Companies like LivaNova are focusing on specialized ECMO systems catering to pediatric and neonatal patients, an underserved segment with major growth potential as children's hospitals expand critical care capabilities.
Expanding Telemedicine Integration: As hospitals seek to improve ECMO patient outcomes, partnerships between ECMO manufacturers and telemedicine providers offer pathways for remote consultations and real-time management, opening new revenue streams for companies such as Medtronic.
US Extracorporeal Membrane Oxygenation Machine Market Revenue (USD Million), 2020-2035
The chart illustrates robust growth in the US ECMO machine market, with revenue rising from USD 135 Million in 2020 to an anticipated USD 1,020 Million in 2035. This trajectory reflects consistent market expansion, driven by increased adoption in hospitals and clinics, greater awareness of ECMO benefits, and ongoing technology enhancement. Notably, the period from 2024 onwards shows an accelerated growth rate, underscoring the influence of expanded use cases beyond critical COVID-19 care and the increasing integration of advanced monitoring and digital health solutions. The data indicates a positive long-term outlook for ECMO machine manufacturers across the country.
US Extracorporeal Membrane Oxygenation Machine Market by Regions Share (%), 2025
The pie chart for 2025 shows regional market share distribution for ECMO machines in the US. The Northeast leads with a 28% share due to the high density of specialty hospitals and academic centers. The Midwest and South regions follow closely, accounting for 25% and 24% respectively, benefiting from large hospital networks and increasing ECMO adoption in tertiary care centers. The West holds a 15% share, while the Southwest represents 8%. Regional growth patterns highlight investments in critical care infrastructure and reflect disparities in hospital capabilities across the US.
Recent Developments in US Extracorporeal Membrane Oxygenation Machine Market
In March 2024, Getinge received emergency use authorization from the FDA for its advanced Servo-n ECMO system, designed to provide precise respiratory support with enhanced patient monitoring features for both adult and pediatric populations. This has significantly increased adoption in top US hospitals and critical care networks.
In April 2024, Medtronic announced a collaboration with Teladoc Health to integrate remote monitoring capabilities into their ECMO platforms. The partnership aims to allow real-time patient data sharing between ICUs and external experts, improving patient outcomes and enabling comprehensive extracorporeal support management.
In May 2024, LivaNova completed its first clinical deployment of a miniaturized neonatal ECMO device at a leading US children's hospital. This device targets the specific requirements of newborns and infants and has already shown promising results with improved survival rates and ease of ICU transferability.
Press Releases